4.4 Review

Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease

Journal

CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 14, Issue 3, Pages 330-339

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026613666131127160118

Keywords

2-hydroxypropyl-beta-cyclodextrin; Niemann-Pick disease type C1; neurodegenerative rare disease; translational research

Funding

  1. NIH [National Center for Advancing Translational Science (NCATS)]
  2. NIH [Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)]
  3. NIH [National Institute of Neurological Disorders & Stroke (NINDS)]
  4. NIH [National Human Genome Research Institute (NHGRI)]
  5. Janssen Research & Development, LLC part of the Janssen Pharmaceutical Companies of Johnson Johnson
  6. Ara Parseghian Medical Research Foundation
  7. National Niemann-Pick Disease Foundation
  8. Dana's Angels Research Trust
  9. Hide & Seek Foundation for Lysosomal Disease Research
  10. Race for Adam

Ask authors/readers for more resources

In 2010, the National Institutes of Health (NIH) established the Therapeutics for Rare and Neglected Diseases (TRND) program within the National Center for Advancing Translational Sciences (NCATS), which was created to stimulate drug discovery and development for rare and neglected tropical diseases through a collaborative model between the NIH, academic scientists, nonprofit organizations, and pharmaceutical and biotechnology companies. This paper describes one of the first TRND programs, the development of 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) for the treatment of Niemann-Pick disease type C1 (NPC1). NPC is a neurodegenerative, autosomal recessive rare disease caused by a mutation in either the NPC1 (about 95% of cases) or the NPC2 gene (about 5% of cases). These mutations affect the intracellular trafficking of cholesterol and other lipids, which leads to a progressive accumulation of unesterified cholesterol and glycosphingolipids in the CNS and visceral organs. Affected individuals typically exhibit ataxia, swallowing problems, seizures, and progressive impairment of motor and intellectual function in early childhood, and usually die in adolescence. There is no disease modifying therapy currently approved for NPC1 in the US. A collaborative drug development program has been established between TRND, public and private partners that has completed the pre-clinical development of HP-beta-CD through IND filing for the current Phase I clinical trial that is underway. Here we discuss how this collaborative effort helped to overcome scientific, clinical and financial challenges facing the development of new drug treatments for rare and neglected diseases, and how it will incentivize the commercialization of HP-beta-CD for the benefit of the NPC patient community.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available